Type 2 Diabetes Mellitus With Cardiovascular Risk Therapeutics
1. Brenzavvy patent expiration
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(2 years from now) | |
| US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(3 years from now) | |
| US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(6 years from now) | |
| US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(5 years from now) | |
| US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Dosage: TABLET
More Information on Dosage
BRENZAVVY family patents
2. Jardiance patent expiration
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment...
JARDIANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(2 years from now) | |
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(4 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(8 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(8 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US12115179 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Feb, 2030
(4 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(3 years from now) | |
| US12433906 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US12263153 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US12427162 | BOEHRINGER INGELHEIM | NA |
Apr, 2034
(8 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(8 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(1 year, 9 months from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(8 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(8 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(4 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(8 years from now) | |
|
US11813275 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(8 years from now) | |
|
US12433906 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
3. Ozempic patent
expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
Treatment: Method of treating type 2 diabetes mellitus; A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indica...
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 months from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(2 years ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(4 years ago) | |
| US12295988 | NOVO | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 months ago) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(11 days from now) | |
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(7 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(11 days from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 months ago) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 months ago) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(11 days from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(6 months from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(6 months from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(11 days from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(6 months from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(11 days from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(11 days from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(6 months from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(1 year, 8 months from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 1 month from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(6 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(4 months ago) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents